RxDoctor Payments Data

Rimma Shaposhnikov, MD

Gastroenterology · Glendale, CANPI 1497886220

Payments from drug & device makers

$19,142in general payments, 2019–2025

Across 74 payments — averaging $258.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Redhill Biopharma Inc.$18K
  • AbbVie$420
  • Regeneron Healthcare Solutions, Inc.$163
  • Sanofi$155
  • Cook Medical LLC$129
  • Novo Nordisk$118
  • plus $236 from 7 others

What the payments were for

  • Consulting fees$6003%
  • Speaking & faculty fees$14,65777%
  • Travel & lodging$2,12411%
  • Food & beverage$1,7319%
  • Education$300%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,142 in reported general payments places this provider in the 80th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$262,244
Medicare patients
799
Services billed
2,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide38$31,903
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates234$14,114
Mesalamine31$12,413
Pantoprazole Sodium616$10,020
DexilantDexlansoprazole11$5,558
Dexlansoprazole DrDexlansoprazole18$4,221
Mesalamine ErMesalamine13$3,702
Famotidine226$3,314
CholestyramineCholestyramine (With Sugar)21$2,933
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,735
Sucralfate35$1,626
Ursodiol11$1,619
Erythromycin Ethylsuccinate15$737
Omeprazole70$727
Prednisone37$334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$420$31,90338 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$29$5,55811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →